Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,228 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,228 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission…(PREMETHEP) | N/A | terminated | Jul 28, 2016 | Centre Georges Francois Leclerc | Insufficient recruitment | Enrollment / accrual |
| NCT03122106 | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and… | Phase 1 | terminated | Apr 20, 2017 | Washington University School of Medicine | Loss of funding | Funding |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral… | Phase 2 | withdrawn | Mar 12, 2021 | Northwestern University | Study inactivated due to zero accruals | Enrollment / accrual |
| NCT04428437 | Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line… | — | terminated | Jun 11, 2020 | Humanity & Health Medical Group Limited | The sponsor withdrawed the sponsorship to the study. | Other (stated, no rule matched) |
| NCT00006046 | Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer | Phase 1 | terminated | May 21, 2003 | Ludwig Institute for Cancer Research | poor recruitment | Enrollment / accrual |
| NCT00769652 | Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer,… | N/A | terminated | Oct 9, 2008 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT03140670 | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not… | Phase 2 | terminated | May 4, 2017 | Abramson Cancer Center at Penn Medicine | Loss of funding | Funding |
| NCT05092750 | Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer | Phase 1 / Phase 2 | withdrawn | Oct 26, 2021 | M.D. Anderson Cancer Center | 0 accrual | Enrollment / accrual |
| NCT02716688 | S-1 and Radiotherapy for Elderly Esophageal Cancer Patients | Phase 2 | withdrawn | Mar 23, 2016 | Zhejiang Provincial People's Hospital | No patients enrolled. | Enrollment / accrual |
| NCT02535988 | Abscopal Effect for Metastatic Colorectal Cancer | Phase 2 | withdrawn | Aug 31, 2015 | Zhejiang Provincial People's Hospital | No recruitment. | Enrollment / accrual |
| NCT03991104 | SOX-based CRT for Esophageal Cancer. | Phase 1 / Phase 2 | withdrawn | Jun 19, 2019 | Zhejiang Provincial People's Hospital | No eligible patients enrolled. We have to withdraw the trial. | Enrollment / accrual |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | terminated | May 27, 2022 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05435053 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer(CHECKPOINT) | Phase 2 | terminated | Jun 28, 2022 | Ismail Gögenur | The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included… | Safety / toxicity |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With…(RELEASE) | Phase 2 | terminated | Sep 23, 2019 | PCI Biotech AS | Recent results from a Phase 3 study are expected to change the standard of care for patients with… | Other (stated, no rule matched) |
| NCT05412706 | Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After…(Bohème) | Phase 2 | withdrawn | Jun 9, 2022 | Ospedale Policlinico San Martino | The Principal Investigator has retired and has not been replaced has retired and a new one has not… | Investigator |
| NCT05043987 | Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With… | Phase 1 | withdrawn | Sep 14, 2021 | Conjupro Biotherapeutics, Inc. | New IND sponsor to initiate a separate study | Other (stated, no rule matched) |
| NCT05379907 | Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer | — | withdrawn | May 18, 2022 | Inova Health Care Services | Determined that the tumor analysis could not be performed in accordance with the protocol. | Other (stated, no rule matched) |
| NCT04566133 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy… | Phase 2 | terminated | Sep 28, 2020 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT01011478 | Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed… | Phase 3 | terminated | Nov 11, 2009 | NSABP Foundation Inc | not stated | Not stated |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The… | Phase 1 | withdrawn | Aug 22, 2022 | M.D. Anderson Cancer Center | Per PI's request | Other (stated, no rule matched) |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal… | Phase 2 | terminated | Aug 26, 2019 | M.D. Anderson Cancer Center | Due to Issues Enrolling Patients | Enrollment / accrual |
| NCT05107661 | Colorectal Screening Strategies in Underserved Populations | — | terminated | Nov 4, 2021 | Virtua Health, Inc. | Preliminary findings revealed to many barriers to successfully complete this trial. | Other (stated, no rule matched) |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT00470353 | Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has… | N/A | terminated | May 7, 2007 | Roswell Park Cancer Institute | Withdrawn due to poor accrual/lack of funding | Enrollment / accrual |
| NCT00658593 | Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic… | Phase 3 | terminated | Apr 15, 2008 | NCIC Clinical Trials Group | due to poor accrual | Enrollment / accrual |
| NCT00601198 | A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer | Phase 2 | terminated | Jan 25, 2008 | University of Cincinnati | Funding support withdrawn | Funding |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT01468623 | Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer…(PROFUSE) | Phase 4 | terminated | Nov 9, 2011 | Myriad Genetic Laboratories, Inc. | Study terminated due to slow enrollment. | Enrollment / accrual |
| NCT04591028 | A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in… | Phase 4 | withdrawn | Oct 19, 2020 | Mayo Clinic | Lack of funding. | Funding |
| NCT05951842 | Anesthesia, TIVA, Balanced Anesthesia, NK Cell | N/A | withdrawn | Jul 19, 2023 | Gangnam Severance Hospital | participants are no longer being examined or receiving intervention | Other (stated, no rule matched) |
| NCT00677924 | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal…(GEN206) | Phase 1 / Phase 2 | terminated | May 15, 2008 | Genmab | Due to changes in portfolio review | Sponsor / business decision |
| NCT04212026 | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic… | Phase 2 | terminated | Dec 26, 2019 | University Hospital, Basel, Switzerland | difficult recruitement | Enrollment / accrual |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2008 | City of Hope Medical Center | Terminated early due a shift in resources after lackluster performance of the drug. | Other (stated, no rule matched) |
| NCT04139967 | Study of Short Course Radiation Therapy for Elderly Patients With Rectal Cancer | N/A | terminated | Oct 25, 2019 | University of Rochester | recruitment rates were too low | Enrollment / accrual |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating… | Phase 1 / Phase 2 | withdrawn | Nov 5, 2021 | University of Rochester | no accrual of eligible participants | Enrollment / accrual |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced…(DEDUCTIVE) | Phase 1 / Phase 2 | terminated | May 31, 2019 | AVEO Pharmaceuticals, Inc. | The study was terminated due to regulatory approval of newer therapeutic options and slower than… | Enrollment / accrual |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | Phase 2 | withdrawn | Oct 29, 2018 | Sun Yat-sen University | No patients join | Other (stated, no rule matched) |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | Aug 21, 2015 | M.D. Anderson Cancer Center | The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was… | Sponsor / business decision |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular… | Phase 2 | terminated | Jul 19, 2018 | Antengene Therapeutics Limited | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III… | Phase 3 | terminated | Mar 17, 2006 | ECOG-ACRIN Cancer Research Group | The study was terminated before reaching its accrual goal due to slow accrual. | Enrollment / accrual |
| NCT00551759 | Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and… | Phase 2 | terminated | Oct 31, 2007 | Eastern Cooperative Oncology Group | The study used a two-stage design. After stage one, the study was terminated due to excess toxicity. | Safety / toxicity |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Phase 2 | terminated | May 30, 2014 | QED Therapeutics, a BridgeBio company | The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints).… | Safety / toxicity |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Phase 2 | withdrawn | Jan 31, 2022 | HonorHealth Research Institute | enrollment challenges | Enrollment / accrual |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT00002525 | Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically… | Phase 3 | terminated | Apr 6, 2004 | ECOG-ACRIN Cancer Research Group | The study was stopped before reaching its accrual goal due to slow accrual | Enrollment / accrual |
| NCT02515513 | The Role of Muscle Cachexia in Pancreatic Cancer | N/A | withdrawn | Aug 4, 2015 | University of Florida | Original PI left the institution. No subjects enrolled | Investigator |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally… | Phase 1 / Phase 2 | terminated | May 4, 2011 | Eisai Inc. | The study was terminated by the Sponsor due to E7820 plus irinotecan being potentially inferior to… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Oct 11, 2023source: clinicaltrials